
Exagen Inc (XGN) Stock Forecast & Price Target
Exagen Inc (XGN) Analyst Ratings
Bulls say
Exagen is a promising medical technology company that offers diagnostic testing products under its AVISE brand for rheumatic and autoimmune diseases. Despite the company beating revenue expectations and showing positive volume and ASP growth, they have chosen to maintain their revenue guide for 2026, which may indicate conservative estimates. However, with an expanding sales force and new biomarker launches, Exagen is poised to dominate a market with significant need and limited competition, positioning them well for long-term growth potential.
Bears say
Exagen is facing several risks that could negatively impact its financial performance and valuation. These include potential challenges with commercial execution, reimbursement issues, payor concentration risks, and single product concentration risk. Additionally, the company operates as a small-cap company and may face difficulties accessing capital and becoming profitable. Other factors that could affect its outlook include competition, management execution, and regulatory risks related to its products.
This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.
Exagen Inc (XGN) Analyst Forecast & Price Prediction
Start investing in Exagen Inc (XGN)
Order type
Buy in
Order amount
Est. shares
0 shares